Venn Life Sciences Holdings Stock London S.E.
Equities
GB00B9275X97
Biotechnology & Medical Research
Sales 2023 | 56.04M 70.1M | Sales 2024 * | 62.91M 78.7M | Capitalization | 195M 243M |
---|---|---|---|---|---|
Net income 2023 | 16M 20.01M | Net income 2024 * | 8M 10.01M | EV / Sales 2023 | 2.88 x |
Net cash position 2023 * | 34.79M 43.52M | Net cash position 2024 * | 43.56M 54.49M | EV / Sales 2024 * | 2.4 x |
P/E ratio 2023 |
10.1
x | P/E ratio 2024 * |
23
x | Employees | - |
Yield 2023 * |
1.42% | Yield 2024 * |
0.82% | Free-Float | 60.8% |
Latest transcript on Venn Life Sciences Holdings
Managers | Title | Age | Since |
---|---|---|---|
Yamin Khan
CEO | Chief Executive Officer | 55 | 21-10-12 |
Ian O'Connell
FOU | Founder | 37 | 11-01-31 |
Cathal Friel
FOU | Founder | 59 | 11-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 22-06-07 | |
Cathal Friel
FOU | Founder | 59 | 11-01-31 |
Brendan Buckley
FOU | Founder | 73 | 18-11-30 |
1st Jan change | Capi. | |
---|---|---|
+1.46% | 42.59B | |
+7.70% | 40.65B | |
+48.49% | 40.57B | |
-11.96% | 26.77B | |
+8.03% | 24.81B | |
-24.69% | 18.17B | |
+28.45% | 12.05B | |
-2.89% | 11.7B | |
+7.31% | 11.1B |